Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone
Liu J, Wang LN
CNS drugs · 44 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
Según 1 financiador declarado.
Publicación
- Publicado
- 2013-11-15 · CNS Drugs · vol. 28 · número 1 · págs. 63–68
- Editorial
- Adis, Springer Healthcare
- Citado
- 53 citas · más que el 31% de estudios similares · 0.3× el promedio de su campo
- Referencias
- 34 trabajos
- Acceso
- De pago
- Áreas de investigación
- Coenzyme Q10 studies and effects · Parkinson's Disease Mechanisms and Treatments · Neurological Disorders and Treatments
- Palabras clave
- neurodegenerative movement disorders, creatine, coenzyme Q10, idebenone, mitoquinone, Parkinson's disease, atypical parkinsonism, Huntington's disease, Friedreich's ataxia, mitochondrial dysfunction, motor symptoms, treatment efficacy
- MeSH
- mitochondria, animals, humans, neurodegenerative diseases, mitochondrial diseases, creatine, organophosphorus compounds, ubiquinone, dose-response relationship, drug, randomized controlled trials as topic
2 autores
- Jia Liu🇨🇳Chinese PLA General Hospital
- Lu‐Ning Wang🇨🇳 · autor de correspondenciaChinese PLA General Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Neurodegenerative movement disorders mainly include Parkinson's disease (PD), atypical parkinsonisms, Huntington's disease (HD), and Friedreich's ataxia (FA). With mitochondrial dysfunction observed in these diseases, mitochondrial enhancement such as creatine, coenzyme Q10 (CoQ10) and its analogues (idebenone and mitoquinone) has been regarded as a potential treatment.
Aim
In this paper, we systematically analysed and summarized the efficacy of mitochondrial enhancement in improving motor and other symptoms in neurodegenerative movement disorders.
Methods
We searched the electronic databases PubMed, EMBASE, CINAHL, Cochrane Library and China National Knowledge Infrastructure until September 2013 for eligible randomized controlled trials (RCTs), as well as unpublished and ongoing trials. We calculated the mean differences for continuous data with 95% confidence intervals and pooled the results using a fixed-effect model, if no significant statistical heterogeneity was found (I(2) < 50%).
Results
We included 16 studies with 1,557 randomized patients, which compared creatine, CoQ10 or its analogues with placebo in motor and other symptoms. No significant improvements were found in the motor symptoms of PD, atypical parkinsonisms or HD patients, while only the high dose of idebenone seems to be promising for motor improvement in FA. Certain benefits are found in other symptoms.
Conclusions
There is insufficient evidence to support the use of mitochondrial enhancement in patients with neurodegenerative movement disorders. More well-designed RCTs with large samples are required for further confirmation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.